Share Price and Basic Stock Data
Last Updated: February 13, 2026, 10:25 pm
| PEG Ratio | 0.00 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Genpharmasec Ltd operates within the Trading & Distributors sector and has reported a market capitalization of ₹74.2 Cr with a share price of ₹1.34. The company’s sales have shown an upward trajectory, with quarterly sales increasing from ₹6.22 Cr in March 2023 to ₹10.20 Cr in March 2024, and further up to ₹32.64 Cr by September 2025. This consistent growth indicates a strong demand for its products. However, the company’s revenue growth has been accompanied by fluctuating expenses, which stood at ₹6.01 Cr in March 2023 and increased to ₹33.10 Cr by September 2025. The trailing twelve-month (TTM) sales reached ₹67.17 Cr, reflecting a healthy increase compared to ₹25.52 Cr reported for the financial year ending March 2023. This trend suggests that Genpharmasec is successfully expanding its market presence, though it must manage its costs effectively to sustain profitability.
Profitability and Efficiency Metrics
In terms of profitability, Genpharmasec Ltd has faced challenges, as indicated by its operating profit margin (OPM), which stood at -1.41% as of the latest reporting period. The operating profit fluctuated significantly, with a peak of ₹0.74 Cr recorded in December 2024, followed by a decline to -₹1.00 Cr in March 2025. The net profit for the financial year ending March 2025 was ₹1.23 Cr, up from a net loss of ₹0.17 Cr in March 2024. The return on equity (ROE) stood at a low 1.90%, while the return on capital employed (ROCE) was slightly better at 3.35%. These figures underscore the need for improved operational efficiency as the company continues to navigate its financial landscape. The cash conversion cycle (CCC) of 146.47 days indicates room for improvement in working capital management, especially as debtor days have increased to 147.21.
Balance Sheet Strength and Financial Ratios
Genpharmasec’s balance sheet reflects a mixed picture, with total borrowings rising to ₹11.01 Cr by September 2025, an increase from ₹3.08 Cr in March 2023. This rise in leverage could pose risks if not managed prudently. The current ratio has declined significantly from 15.16 to 2.78, indicating potential liquidity issues, while the interest coverage ratio (ICR), which stood at 7.19, suggests that the company has sufficient earnings to cover its interest obligations. The book value per share increased marginally from ₹1.17 in March 2024 to ₹1.18 in March 2025, indicating a slight strengthening of equity. Furthermore, the company’s total assets grew from ₹19.87 Cr in March 2023 to ₹124.00 Cr by September 2025, reflecting strategic investments, particularly in fixed assets, which rose to ₹42.20 Cr.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Genpharmasec Ltd reveals a significant shift in promoter holdings, which decreased from 59.96% in March 2023 to 29.98% by March 2025. This dilution raises questions about management confidence and alignment with minority shareholders. Conversely, public ownership increased from 40.03% to 70.02% during the same period, indicating growing interest among retail investors, with the total number of shareholders reaching 1,05,804 by September 2025. The substantial public interest could suggest potential for increased market liquidity, although it may also reflect concerns regarding the company’s governance structure. The lack of foreign institutional and domestic institutional investors could signal hesitancy among larger investors, potentially affecting stock stability and growth prospects.
Outlook, Risks, and Final Insight
Looking ahead, Genpharmasec Ltd has the potential to benefit from its revenue growth trajectory; however, it faces several risks that could impact its performance. The high cash conversion cycle and declining profitability margins suggest that operational efficiencies must be prioritized. Additionally, the rising debt levels could pose challenges if the company fails to convert revenues into sustainable profits. Nevertheless, the increased public interest and shareholder base may provide a buffer against volatility. A strategic focus on cost management and operational efficiency could enhance profitability while maintaining investor confidence. The company must navigate these dynamics carefully, as its operational decisions will significantly shape future outcomes.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Millennium Online Solutions (India) Ltd | 7.80 Cr. | 1.56 | 2.88/1.36 | 0.81 | 0.00 % | 4.61 % | 5.54 % | 1.00 | |
| Minal Industries Ltd | 54.7 Cr. | 2.85 | 5.59/2.50 | 133 | 2.78 | 0.00 % | 5.97 % | 2.83 % | 2.00 |
| Mitshi India Ltd | 12.3 Cr. | 14.0 | 17.5/11.5 | 3.09 | 0.00 % | 0.36 % | 0.37 % | 10.0 | |
| Modella Woollens Ltd | 5.95 Cr. | 65.4 | 74.8/52.5 | 4.95 | 0.00 % | % | % | 10.0 | |
| MRC Agrotech Ltd | 134 Cr. | 42.8 | 54.5/10.2 | 149 | 15.1 | 0.00 % | 5.89 % | 4.46 % | 10.0 |
| Industry Average | 8,813.16 Cr | 153.45 | 104.25 | 119.20 | 0.42% | 15.22% | 8.81% | 7.62 |
Quarterly Result
| Metric | Mar 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 6.22 | 7.86 | 6.38 | 10.20 | 5.20 | 6.03 | 8.48 | 14.01 | 12.04 | 32.64 |
| Expenses | 6.01 | 7.89 | 6.37 | 10.21 | 5.00 | 5.90 | 7.74 | 15.01 | 11.10 | 33.10 |
| Operating Profit | 0.21 | -0.03 | 0.01 | -0.01 | 0.20 | 0.13 | 0.74 | -1.00 | 0.94 | -0.46 |
| OPM % | 3.38% | -0.38% | 0.16% | -0.10% | 3.85% | 2.16% | 8.73% | -7.14% | 7.81% | -1.41% |
| Other Income | 0.06 | 0.15 | 0.14 | 0.31 | 0.57 | 0.75 | 0.81 | 0.94 | 0.69 | 0.46 |
| Interest | 0.06 | 0.07 | 0.00 | 0.16 | 0.10 | 0.07 | 0.16 | 0.11 | 0.12 | 0.23 |
| Depreciation | 0.01 | 0.00 | 0.12 | 0.03 | 0.16 | 0.30 | 0.10 | 0.26 | 0.27 | 0.56 |
| Profit before tax | 0.20 | 0.05 | 0.03 | 0.11 | 0.51 | 0.51 | 1.29 | -0.43 | 1.24 | -0.79 |
| Tax % | -420.00% | 80.00% | -100.00% | 345.45% | 35.29% | -39.22% | 39.53% | -37.21% | 2.42% | 48.10% |
| Net Profit | 1.05 | 0.01 | 0.06 | -0.27 | 0.33 | 0.70 | 0.78 | -0.27 | 1.22 | -1.18 |
| EPS in Rs | 0.02 | 0.00 | 0.00 | -0.00 | 0.01 | 0.01 | 0.01 | -0.00 | 0.02 | -0.02 |
Last Updated: December 26, 2025, 7:16 pm
Below is a detailed analysis of the quarterly data for Genpharmasec Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 32.64 Cr.. The value appears strong and on an upward trend. It has increased from 12.04 Cr. (Jun 2025) to 32.64 Cr., marking an increase of 20.60 Cr..
- For Expenses, as of Sep 2025, the value is 33.10 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 11.10 Cr. (Jun 2025) to 33.10 Cr., marking an increase of 22.00 Cr..
- For Operating Profit, as of Sep 2025, the value is -0.46 Cr.. The value appears to be declining and may need further review. It has decreased from 0.94 Cr. (Jun 2025) to -0.46 Cr., marking a decrease of 1.40 Cr..
- For OPM %, as of Sep 2025, the value is -1.41%. The value appears to be declining and may need further review. It has decreased from 7.81% (Jun 2025) to -1.41%, marking a decrease of 9.22%.
- For Other Income, as of Sep 2025, the value is 0.46 Cr.. The value appears to be declining and may need further review. It has decreased from 0.69 Cr. (Jun 2025) to 0.46 Cr., marking a decrease of 0.23 Cr..
- For Interest, as of Sep 2025, the value is 0.23 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.12 Cr. (Jun 2025) to 0.23 Cr., marking an increase of 0.11 Cr..
- For Depreciation, as of Sep 2025, the value is 0.56 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.27 Cr. (Jun 2025) to 0.56 Cr., marking an increase of 0.29 Cr..
- For Profit before tax, as of Sep 2025, the value is -0.79 Cr.. The value appears to be declining and may need further review. It has decreased from 1.24 Cr. (Jun 2025) to -0.79 Cr., marking a decrease of 2.03 Cr..
- For Tax %, as of Sep 2025, the value is 48.10%. The value appears to be increasing, which may not be favorable. It has increased from 2.42% (Jun 2025) to 48.10%, marking an increase of 45.68%.
- For Net Profit, as of Sep 2025, the value is -1.18 Cr.. The value appears to be declining and may need further review. It has decreased from 1.22 Cr. (Jun 2025) to -1.18 Cr., marking a decrease of 2.40 Cr..
- For EPS in Rs, as of Sep 2025, the value is -0.02. The value appears to be declining and may need further review. It has decreased from 0.02 (Jun 2025) to -0.02, marking a decrease of 0.04.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 3:40 am
| Metric | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|
| Sales | 25.52 | 30.41 | 33.57 | 67.17 |
| Expenses | 25.26 | 30.37 | 33.49 | 66.95 |
| Operating Profit | 0.26 | 0.04 | 0.08 | 0.22 |
| OPM % | 1.02% | 0.13% | 0.24% | 0.33% |
| Other Income | 0.10 | 0.66 | 3.06 | 2.90 |
| Interest | 0.06 | 0.41 | 0.45 | 0.62 |
| Depreciation | 0.02 | 0.04 | 0.81 | 1.19 |
| Profit before tax | 0.28 | 0.25 | 1.88 | 1.31 |
| Tax % | -300.00% | 168.00% | 34.57% | |
| Net Profit | 1.12 | -0.17 | 1.23 | 0.55 |
| EPS in Rs | 0.02 | -0.00 | 0.02 | 0.01 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2023-2024 | 2024-2025 |
|---|---|---|
| YoY Net Profit Growth (%) | -115.18% | 823.53% |
| Change in YoY Net Profit Growth (%) | 0.00% | 938.71% |
Genpharmasec Ltd has shown a consistent positive trend in YoY Net Profit Growth (%) in the last 2 years from 2023-2024 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 37% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 1769% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 22% |
| 5 Years: | -22% |
| 3 Years: | -9% |
| 1 Year: | -44% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | 2% |
Last Updated: September 5, 2025, 3:36 pm
Balance Sheet
Last Updated: December 4, 2025, 2:57 am
| Month | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|
| Equity Capital | 27.69 | 55.37 | 55.37 | 55.37 |
| Reserves | -12.36 | 9.02 | 9.79 | 10.31 |
| Borrowings | 3.08 | 3.89 | 5.28 | 11.01 |
| Other Liabilities | 1.46 | 2.84 | 9.45 | 47.31 |
| Total Liabilities | 19.87 | 71.12 | 79.89 | 124.00 |
| Fixed Assets | 0.10 | 0.84 | 7.58 | 42.20 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.95 | 19.32 | 18.84 | 2.05 |
| Other Assets | 18.82 | 50.96 | 53.47 | 79.75 |
| Total Assets | 19.87 | 71.12 | 79.89 | 124.00 |
Below is a detailed analysis of the balance sheet data for Genpharmasec Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 55.37 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 55.37 Cr..
- For Reserves, as of Sep 2025, the value is 10.31 Cr.. The value appears strong and on an upward trend. It has increased from 9.79 Cr. (Mar 2025) to 10.31 Cr., marking an increase of 0.52 Cr..
- For Borrowings, as of Sep 2025, the value is 11.01 Cr.. The value appears to be increasing, which may not be favorable. However, Borrowings exceed Reserves, which may signal higher financial risk. It has increased from 5.28 Cr. (Mar 2025) to 11.01 Cr., marking an increase of 5.73 Cr..
- For Other Liabilities, as of Sep 2025, the value is 47.31 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 9.45 Cr. (Mar 2025) to 47.31 Cr., marking an increase of 37.86 Cr..
- For Total Liabilities, as of Sep 2025, the value is 124.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 79.89 Cr. (Mar 2025) to 124.00 Cr., marking an increase of 44.11 Cr..
- For Fixed Assets, as of Sep 2025, the value is 42.20 Cr.. The value appears strong and on an upward trend. It has increased from 7.58 Cr. (Mar 2025) to 42.20 Cr., marking an increase of 34.62 Cr..
- For CWIP, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Investments, as of Sep 2025, the value is 2.05 Cr.. The value appears to be declining and may need further review. It has decreased from 18.84 Cr. (Mar 2025) to 2.05 Cr., marking a decrease of 16.79 Cr..
- For Other Assets, as of Sep 2025, the value is 79.75 Cr.. The value appears strong and on an upward trend. It has increased from 53.47 Cr. (Mar 2025) to 79.75 Cr., marking an increase of 26.28 Cr..
- For Total Assets, as of Sep 2025, the value is 124.00 Cr.. The value appears strong and on an upward trend. It has increased from 79.89 Cr. (Mar 2025) to 124.00 Cr., marking an increase of 44.11 Cr..
However, the Borrowings (11.01 Cr.) are higher than the Reserves (10.31 Cr.), which may signal higher financial risk.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|
Free Cash Flow
| Month | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|
| Free Cash Flow | -2.82 | -3.85 | -5.20 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|
| Debtor Days | 81.67 | 109.22 | 147.21 |
| Inventory Days | 151.06 | 133.17 | 101.29 |
| Days Payable | 21.38 | 35.85 | 102.03 |
| Cash Conversion Cycle | 211.34 | 206.54 | 146.47 |
| Working Capital Days | 199.09 | 213.17 | 141.26 |
| ROCE % | 1.52% | 3.32% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 |
|---|---|---|
| FaceValue | 1.00 | 1.00 |
| Basic EPS (Rs.) | 0.02 | -0.01 |
| Diluted EPS (Rs.) | 0.02 | -0.01 |
| Cash EPS (Rs.) | 0.03 | 0.00 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 1.18 | 1.17 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 1.18 | 1.17 |
| Revenue From Operations / Share (Rs.) | 0.60 | 0.54 |
| PBDIT / Share (Rs.) | 0.05 | 0.01 |
| PBIT / Share (Rs.) | 0.04 | 0.01 |
| PBT / Share (Rs.) | 0.03 | 0.00 |
| Net Profit / Share (Rs.) | 0.02 | 0.00 |
| NP After MI And SOA / Share (Rs.) | 0.02 | 0.00 |
| PBDIT Margin (%) | 9.27 | 2.30 |
| PBIT Margin (%) | 6.86 | 2.16 |
| PBT Margin (%) | 5.57 | 0.82 |
| Net Profit Margin (%) | 3.65 | -0.55 |
| NP After MI And SOA Margin (%) | 3.58 | -0.41 |
| Return on Networth / Equity (%) | 1.85 | -0.19 |
| Return on Capital Employeed (%) | 3.30 | 0.96 |
| Return On Assets (%) | 1.51 | -0.17 |
| Long Term Debt / Equity (X) | 0.04 | 0.04 |
| Total Debt / Equity (X) | 0.04 | 0.04 |
| Asset Turnover Ratio (%) | 0.44 | 0.00 |
| Current Ratio (X) | 2.78 | 15.16 |
| Quick Ratio (X) | 1.94 | 11.89 |
| Inventory Turnover Ratio (X) | 3.96 | 0.00 |
| Interest Coverage Ratio (X) | 7.19 | 1.72 |
| Interest Coverage Ratio (Post Tax) (X) | 3.83 | 0.58 |
| Enterprise Value (Cr.) | 102.64 | 108.00 |
| EV / Net Operating Revenue (X) | 3.04 | 3.55 |
| EV / EBITDA (X) | 32.83 | 153.89 |
| MarketCap / Net Operating Revenue (X) | 3.10 | 4.06 |
| Price / BV (X) | 1.61 | 1.92 |
| Price / Net Operating Revenue (X) | 3.10 | 4.06 |
| EarningsYield | 0.01 | 0.00 |
After reviewing the key financial ratios for Genpharmasec Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 0.02. This value is below the healthy minimum of 5. It has increased from -0.01 (Mar 24) to 0.02, marking an increase of 0.03.
- For Diluted EPS (Rs.), as of Mar 25, the value is 0.02. This value is below the healthy minimum of 5. It has increased from -0.01 (Mar 24) to 0.02, marking an increase of 0.03.
- For Cash EPS (Rs.), as of Mar 25, the value is 0.03. This value is below the healthy minimum of 3. It has increased from 0.00 (Mar 24) to 0.03, marking an increase of 0.03.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 1.18. It has increased from 1.17 (Mar 24) to 1.18, marking an increase of 0.01.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 1.18. It has increased from 1.17 (Mar 24) to 1.18, marking an increase of 0.01.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 0.60. It has increased from 0.54 (Mar 24) to 0.60, marking an increase of 0.06.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 0.05. This value is below the healthy minimum of 2. It has increased from 0.01 (Mar 24) to 0.05, marking an increase of 0.04.
- For PBIT / Share (Rs.), as of Mar 25, the value is 0.04. This value is within the healthy range. It has increased from 0.01 (Mar 24) to 0.04, marking an increase of 0.03.
- For PBT / Share (Rs.), as of Mar 25, the value is 0.03. This value is within the healthy range. It has increased from 0.00 (Mar 24) to 0.03, marking an increase of 0.03.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 0.02. This value is below the healthy minimum of 2. It has increased from 0.00 (Mar 24) to 0.02, marking an increase of 0.02.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 0.02. This value is below the healthy minimum of 2. It has increased from 0.00 (Mar 24) to 0.02, marking an increase of 0.02.
- For PBDIT Margin (%), as of Mar 25, the value is 9.27. This value is below the healthy minimum of 10. It has increased from 2.30 (Mar 24) to 9.27, marking an increase of 6.97.
- For PBIT Margin (%), as of Mar 25, the value is 6.86. This value is below the healthy minimum of 10. It has increased from 2.16 (Mar 24) to 6.86, marking an increase of 4.70.
- For PBT Margin (%), as of Mar 25, the value is 5.57. This value is below the healthy minimum of 10. It has increased from 0.82 (Mar 24) to 5.57, marking an increase of 4.75.
- For Net Profit Margin (%), as of Mar 25, the value is 3.65. This value is below the healthy minimum of 5. It has increased from -0.55 (Mar 24) to 3.65, marking an increase of 4.20.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 3.58. This value is below the healthy minimum of 8. It has increased from -0.41 (Mar 24) to 3.58, marking an increase of 3.99.
- For Return on Networth / Equity (%), as of Mar 25, the value is 1.85. This value is below the healthy minimum of 15. It has increased from -0.19 (Mar 24) to 1.85, marking an increase of 2.04.
- For Return on Capital Employeed (%), as of Mar 25, the value is 3.30. This value is below the healthy minimum of 10. It has increased from 0.96 (Mar 24) to 3.30, marking an increase of 2.34.
- For Return On Assets (%), as of Mar 25, the value is 1.51. This value is below the healthy minimum of 5. It has increased from -0.17 (Mar 24) to 1.51, marking an increase of 1.68.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.04. This value is below the healthy minimum of 0.2. There is no change compared to the previous period (Mar 24) which recorded 0.04.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.04. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 0.04.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.44. It has increased from 0.00 (Mar 24) to 0.44, marking an increase of 0.44.
- For Current Ratio (X), as of Mar 25, the value is 2.78. This value is within the healthy range. It has decreased from 15.16 (Mar 24) to 2.78, marking a decrease of 12.38.
- For Quick Ratio (X), as of Mar 25, the value is 1.94. This value is within the healthy range. It has decreased from 11.89 (Mar 24) to 1.94, marking a decrease of 9.95.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 3.96. This value is below the healthy minimum of 4. It has increased from 0.00 (Mar 24) to 3.96, marking an increase of 3.96.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 7.19. This value is within the healthy range. It has increased from 1.72 (Mar 24) to 7.19, marking an increase of 5.47.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 3.83. This value is within the healthy range. It has increased from 0.58 (Mar 24) to 3.83, marking an increase of 3.25.
- For Enterprise Value (Cr.), as of Mar 25, the value is 102.64. It has decreased from 108.00 (Mar 24) to 102.64, marking a decrease of 5.36.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 3.04. This value exceeds the healthy maximum of 3. It has decreased from 3.55 (Mar 24) to 3.04, marking a decrease of 0.51.
- For EV / EBITDA (X), as of Mar 25, the value is 32.83. This value exceeds the healthy maximum of 15. It has decreased from 153.89 (Mar 24) to 32.83, marking a decrease of 121.06.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 3.10. This value exceeds the healthy maximum of 3. It has decreased from 4.06 (Mar 24) to 3.10, marking a decrease of 0.96.
- For Price / BV (X), as of Mar 25, the value is 1.61. This value is within the healthy range. It has decreased from 1.92 (Mar 24) to 1.61, marking a decrease of 0.31.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 3.10. This value exceeds the healthy maximum of 3. It has decreased from 4.06 (Mar 24) to 3.10, marking a decrease of 0.96.
- For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. It has increased from 0.00 (Mar 24) to 0.01, marking an increase of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Genpharmasec Ltd:
- Net Profit Margin: 3.65%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 3.3% (Industry Average ROCE: 15.22%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 1.85% (Industry Average ROE: 8.81%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 3.83
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.94
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 0 (Industry average Stock P/E: 104.25)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.04
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 3.65%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Trading & Distributors | Office No. 104 & 105 (1st Floor), Gundecha Industrial Premises Co-Operative Society Ltd., Mumbai Maharashtra 400101 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Sohan Chaturvedi | WholeTime Director & CFO |
| Mrs. Sneha Sadhwani | Non Exe.Non Ind.Director |
| Mr. Rajesh Sadhwani | Non Exe.Non Ind.Director |
| Mr. Siddhesh Shende | Independent Director |
| Mr. Mayur Bhatt | Independent Director |
| Mr. Sachin Aphandkar | Independent Director |
FAQ
What is the intrinsic value of Genpharmasec Ltd?
Genpharmasec Ltd's intrinsic value (as of 14 February 2026) is ₹0.24 which is 81.82% lower the current market price of ₹1.32, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹73.1 Cr. market cap, FY2025-2026 high/low of ₹2.40/0.98, reserves of ₹10.31 Cr, and liabilities of ₹124.00 Cr.
What is the Market Cap of Genpharmasec Ltd?
The Market Cap of Genpharmasec Ltd is 73.1 Cr..
What is the current Stock Price of Genpharmasec Ltd as on 14 February 2026?
The current stock price of Genpharmasec Ltd as on 14 February 2026 is ₹1.32.
What is the High / Low of Genpharmasec Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Genpharmasec Ltd stocks is ₹2.40/0.98.
What is the Stock P/E of Genpharmasec Ltd?
The Stock P/E of Genpharmasec Ltd is .
What is the Book Value of Genpharmasec Ltd?
The Book Value of Genpharmasec Ltd is 1.19.
What is the Dividend Yield of Genpharmasec Ltd?
The Dividend Yield of Genpharmasec Ltd is 0.00 %.
What is the ROCE of Genpharmasec Ltd?
The ROCE of Genpharmasec Ltd is 3.35 %.
What is the ROE of Genpharmasec Ltd?
The ROE of Genpharmasec Ltd is 1.90 %.
What is the Face Value of Genpharmasec Ltd?
The Face Value of Genpharmasec Ltd is 1.00.